A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and Cellipont Bioservices, a cell therapy contract development and ...

Aspen's sasineprocel is an autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) ...

Japan’s move to conditionally approve two induced pluripotent stem cell derived therapies marks a significant development for ...

The blood-brain barrier protects the central nervous system by tightly regulating what crosses between the two compartments. Neurons are vulnerable if the barrier suffers damage or weakens with age, ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Induced pluripotent stem cells (iPSCs) are a “starting material grail” for advanced therapies. That’s according to Sven Kili, chief development officer at CCRM, the Canadian regenerative medicine ...

With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and ...